6 results about "Multigene expression" patented technology

This invention discloses the application of a biomarker in assessing the risk of prostate cancer recurrence, belonging to the field of tumor molecular diagnostics and bioinformatics technology. The biomarker includes at least one of the TACR2 and LPIN3 genes, and RCCD1, PRSS27, and NAP1L5, with the core detection focusing on the methylation-transcriptional combined characteristics of the TACR2 gene. This invention obtains patient samples, uses RT-qPCR to detect the expression levels of multiple genes, and methylation-specific PCR to detect the methylation level of the TACR2 promoter region. A risk scoring model is constructed using LASSO regression, and patient prognosis is stratified based on the score. This invention solves the problems of traditional assessment indicators being affected by tumor heterogeneity and having limited predictive accuracy. It is the first to use TACR2-related multi-omics characteristics for prostate cancer recurrence assessment. The multi-gene combined model improves predictive accuracy and can be developed into a standardized testing kit, providing a scientific basis for clinical recurrence risk assessment and personalized treatment, with significant industrial and clinical application value.

The present invention provides transgenic animals (e.g., transgenic porcine animals), organs, tissues, and cells derived from the transgenic animals that are particularly useful for xenotransplantation therapies. In particular, the present invention provides transgenic porcine animals, as well as organs, tissues and cells derived from the transgenic porcine animals, which lack any expression of a functional alpha 1,3 galactosyltransferase (GTKO) gene and comprise at least six transgenes under the control of at least three promoters within a single multi-gene expression vector, and further comprise at least four additional genetic modifications. Also provided are methods of making the transgenic animals (e.g., transgenic porcine animals), and methods of using the transgenic animals, organs, tissues, and cells derived from the transgenic animals for xenotransplantation therapies and treating a disease or condition.

This application relates to the field of molecular subtyping technology, specifically disclosing a molecular subtyping method for NK / T-cell lymphoma based on multi-gene expression characteristics and its application. The molecular subtyping method provided in this application can systematically reflect the molecular heterogeneity of NK / T-cell lymphoma, offers a standardized and reproducible molecular subtyping detection protocol, and can also assist in assessing patient prognostic risks and provide a reference for treatment decisions. The molecular subtyping method provided in this application is applicable to various conventional molecular detection platforms and has good clinical application value.

The invention relates to a method of predicting an outcome of a breast cancer subject, comprising determining or receiving the result of a determination of a gene expression profile comprising the expression levels of four or more genes selected from a first, a second and / or a third gene expression profile, wherein the first gene expression profile comprising one or more immune defense response genes selected from the group consisting of: AIM2, APOBEC3A, CIAO1, DDX58, DHX9, IFI16, IFIH1, IFIT1, IFIT3, LRRFIP1, MYD88, OAS1, TLR8, and ZBP1, and / or the second gene expression profile comprising one or more T-Cell receptor signalling genes selected from the group consisting of: CD2, CD247, CD28, CD3E, CD3G, CD4, CSK, EZR, FYN, LAT, LCK, PAG1, PDE4D, PRKACA, PRKACB, PTPRC, and ZAP70, and / or the third gene expression profile comprising one or more PDE4D7 correlated genes selected from the group consisting of: ABCC5, CUX2, KIAA1549, PDE4D, RAP1GAP2, SLC39A11, TDRD1, and VWA2, said gene expression profile being determined in a biological sample obtained from the subject, determining the prediction of the outcome based on the gene expression profile comprising the expression levels of the four or more genes, wherein said prediction is a favourable risk or a non-favourable risk of breast-cancer related death, loco-regional recurrence and / or distant recurrence.

The application discloses a tumor and paired cell line whole transcriptome RNA standard substance and a preparation method and application, wherein the tumor and paired cell line is a lung cancer and paired paracancer tissue immortalized cell line, is preserved in the China General Microbiological Culture Collection Center, and the preservation date is October 11, 2025; the lung cancer cell line biological preservation number is CGMCC No. 46703; and the paired paracancer tissue cell line biological preservation number is CGMCC No. 46704. The RNA standard substance includes two samples, is whole transcriptome RNA extracts of the tumor and paracancer tissue immortalized cell line of the same individual source in the Chinese genetic background, and the quantity value is the copy number concentration and the ratio of high confidence genes in the two samples. The whole transcriptome RNA standard substance can be used for performance evaluation of absolute quantification or relative quantification of multi-gene expression of detection data of different transcriptome sequencing technologies and sequencing platforms.

The present invention provides transgenic animals (e.g., transgenic porcine animals), organs, tissues, and cells derived from the transgenic animals that are particularly useful for xenotransplantation therapies. In particular, the present invention provides transgenic porcine animals, as well as organs, tissues and cells derived from the transgenic porcine animals, which lack any expression of a functional alpha 1,3 galactosyltransferase (GTKO) gene and comprise at least six transgenes under the control of at least three promoters within a single multi-gene expression vector, and further comprise at least four additional genetic modifications. Also provided are methods of making the transgenic animals (e.g., transgenic porcine animals), and methods of using the transgenic animals, organs, tissues, and cells derived from the transgenic animals for xenotransplantation therapies and treating a disease or condition.